Influence of the unbound concentration of cefonicid on its renal elimination in isolated perfused rat kidneys
- PMID: 1804013
- PMCID: PMC245391
- DOI: 10.1128/AAC.35.11.2395
Influence of the unbound concentration of cefonicid on its renal elimination in isolated perfused rat kidneys
Abstract
The effect of variations in plasma protein binding on the renal excretion of cefonicid was assessed by using isolated perfused rat kidneys. Cefonicid exhibits preferential binding ex vivo to human serum albumin (HSA), as opposed to bovine serum albumin (BSA), and is eliminated mainly by tubular secretion, a process that was reported to be dependent on the total drug concentration. This contradicts previous studies with antimicrobial compounds and other drugs of low renal extraction in which the unbound drug concentration was shown to be the driving force for carrier-mediated tubular transport. To clarify this discrepancy, we performed perfusion studies by using 6% BSA at initial concentrations of 200 micrograms/ml (n = 6) and 20 micrograms/ml (n = 9) and in a combination of 4% BSA plus 2% HSA at initial concentrations of 200 micrograms/ml (n = 4). The excretion ratio [ER = CLR/(fu x GFR)] of cefonicid decreased with increasing unbound concentrations, whereas no apparent relationship with the total concentration was evident. At similar total concentrations of cefonicid, the renal clearance remained unchanged; the secretion clearance increased significantly in the 4% BSA-2% HSA experiments, reflecting the reduced unbound fraction and unbound drug concentration of cefonicid. The excretion ratio data were compatible with a model in which Michaelis-Menten kinetics were required to describe active transport and secretion was dependent on the unbound cefonicid concentration. As a result, changes in plasma protein binding as a result of drug interactions or disease states could significantly influence the tubular transport capability of compounds with low renal extraction.
Similar articles
-
Influence of angiotensin II-induced alterations in renal flow on excretion of cefonicid in isolated perfused rat kidneys.Antimicrob Agents Chemother. 1992 Mar;36(3):616-9. doi: 10.1128/AAC.36.3.616. Antimicrob Agents Chemother. 1992. PMID: 1622172 Free PMC article.
-
Renal transport kinetics of furosemide in the isolated perfused rat kidney.J Pharmacokinet Biopharm. 1986 Apr;14(2):157-74. doi: 10.1007/BF01065259. J Pharmacokinet Biopharm. 1986. PMID: 3746637
-
Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans.Antimicrob Agents Chemother. 1986 Oct;30(4):565-9. doi: 10.1128/AAC.30.4.565. Antimicrob Agents Chemother. 1986. PMID: 3789691 Free PMC article.
-
Renal excretion and accumulation kinetics of 2-methylbenzoylglycine in the isolated perfused rat kidney.J Pharm Pharmacol. 1996 Jun;48(6):560-5. doi: 10.1111/j.2042-7158.1996.tb05974.x. J Pharm Pharmacol. 1996. PMID: 8832487
-
Saturable pharmacokinetics in the renal excretion of drugs.Clin Pharmacokinet. 1989 Jan;16(1):38-54. doi: 10.2165/00003088-198916010-00003. Clin Pharmacokinet. 1989. PMID: 2650954 Review.
Cited by
-
Disposition of quinapril and quinaprilat in the isolated perfused rat kidney.J Pharmacokinet Biopharm. 1995 Jun;23(3):287-305. doi: 10.1007/BF02354286. J Pharmacokinet Biopharm. 1995. PMID: 8834197
-
Drug interactions at the renal level. Implications for drug development.Clin Pharmacokinet. 1998 May;34(5):375-404. doi: 10.2165/00003088-199834050-00004. Clin Pharmacokinet. 1998. PMID: 9592621 Review.
-
Effects of organic anion, organic cation, and dipeptide transport inhibitors on cefdinir in the isolated perfused rat kidney.Antimicrob Agents Chemother. 2003 Feb;47(2):689-96. doi: 10.1128/AAC.47.2.689-696.2003. Antimicrob Agents Chemother. 2003. PMID: 12543679 Free PMC article.
-
Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding.Pharmaceutics. 2019 Jun 18;11(6):286. doi: 10.3390/pharmaceutics11060286. Pharmaceutics. 2019. PMID: 31216743 Free PMC article.
-
Proton-Coupled Oligopeptide Transport (Slc15) in the Brain: Past and Future Research.Pharm Res. 2023 Nov;40(11):2533-2540. doi: 10.1007/s11095-023-03550-9. Epub 2023 Jun 12. Pharm Res. 2023. PMID: 37308743 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials